Viveve Medical Inc (VIVE) Given Average Recommendation of “Buy” by Analysts

Share on StockTwits

Viveve Medical Inc (NASDAQ:VIVE) has been assigned a consensus recommendation of “Buy” from the six research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $6.33.

Several equities research analysts have recently issued reports on the stock. Maxim Group restated a “buy” rating on shares of Viveve Medical in a research note on Thursday. ValuEngine lowered shares of Viveve Medical from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th. Finally, Raymond James decreased their price target on shares of Viveve Medical from $4.50 to $3.00 and set an “outperform” rating for the company in a research note on Wednesday, December 12th.

Institutional investors have recently added to or reduced their stakes in the stock. Granahan Investment Management Inc. MA grew its stake in Viveve Medical by 117.8% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 792,607 shares of the company’s stock valued at $2,156,000 after buying an additional 428,708 shares in the last quarter. Marshall Wace LLP grew its stake in Viveve Medical by 11.0% in the 2nd quarter. Marshall Wace LLP now owns 441,279 shares of the company’s stock valued at $1,200,000 after buying an additional 43,842 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new position in Viveve Medical in the 2nd quarter valued at approximately $268,000. Institutional investors and hedge funds own 56.05% of the company’s stock.

Shares of VIVE stock traded up $0.04 during trading hours on Tuesday, hitting $1.20. 254,497 shares of the company were exchanged, compared to its average volume of 276,235. The company has a debt-to-equity ratio of 3.42, a quick ratio of 3.20 and a current ratio of 3.72. Viveve Medical has a 52-week low of $0.93 and a 52-week high of $4.93.

Viveve Medical (NASDAQ:VIVE) last issued its quarterly earnings results on Friday, November 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.06). Viveve Medical had a negative return on equity of 838.28% and a negative net margin of 243.98%. The company had revenue of $4.82 million for the quarter, compared to analysts’ expectations of $4.60 million. On average, sell-side analysts forecast that Viveve Medical will post -1.56 EPS for the current year.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.

Recommended Story: What are CEFs?

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

U.S. Silica  Given a $15.00 Price Target by Bank of America Analysts
U.S. Silica Given a $15.00 Price Target by Bank of America Analysts
MERIAN GLOBAL INVESTORS UK Ltd Purchases New Position in Bed Bath & Beyond Inc.
MERIAN GLOBAL INVESTORS UK Ltd Purchases New Position in Bed Bath & Beyond Inc.
Southwest Gas  Lifted to Buy at ValuEngine
Southwest Gas Lifted to Buy at ValuEngine
MERIAN GLOBAL INVESTORS UK Ltd Reduces Position in Valero Energy Co.
MERIAN GLOBAL INVESTORS UK Ltd Reduces Position in Valero Energy Co.
Acacia Communications  Issues Quarterly  Earnings Results
Acacia Communications Issues Quarterly Earnings Results
Condensate One Day Volume Reaches $31.00
Condensate One Day Volume Reaches $31.00


Leave a Reply

 
© 2006-2019 Zolmax.